A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation

81Citations
Citations of this article
96Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Although human antibodies elicited by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein are profoundly boosted upon infection, little is known about the function of N-reactive antibodies. Herein, we isolate and profile a panel of 32 N protein-specific monoclonal antibodies (mAbs) from a quick recovery coronavirus disease-19 (COVID-19) convalescent patient who has dominant antibody responses to the SARS-CoV-2 N protein rather than to the SARS-CoV-2 spike (S) protein. The complex structure of the N protein RNA binding domain with the highest binding affinity mAb (nCoV396) reveals changes in the epitopes and antigen’s allosteric regulation. Functionally, a virus-free complement hyperactivation analysis demonstrates that nCoV396 specifically compromises the N protein-induced complement hyperactivation, which is a risk factor for the morbidity and mortality of COVID-19 patients, thus laying the foundation for the identification of functional anti-N protein mAbs.

Cite

CITATION STYLE

APA

Kang, S., Yang, M., He, S., Wang, Y., Chen, X., Chen, Y. Q., … Chen, S. (2021). A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-23036-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free